Physician profile
Richard Chan
NPI 1275506438
$513,537.95
in general payments reported to CMS, 2019-2025
21 companies · $34K in 2025
The $34K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122K · 2020: $44K · 2021: $38K · 2022: $96K · 2023: $74K · 2024: $104K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $148K · Travel and Lodging: $28K · Honoraria: $17K · Food and Beverage: $11K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,100 · Consulting Fee: $3,315 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $147,517.50 |
| Travel and Lodging | $27,698.61 |
| Honoraria | $17,150.00 |
| Food and Beverage | $11,321.51 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,100.00 |
| Consulting Fee | $3,315.04 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $182,189.49 | 2019-2023 | Krystexxa |
| Travere Therapeutics, INC. | $70,059.57 | 2021-2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $66,285.16 | 2019-2024 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $58,290.04 | 2021-2025 | |
| Gilead Sciences, INC. | $42,515.92 | 2019-2024 | Vemlidy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22,866.58 | 2024-2025 | Jardiance |
| Lilly USA, LLC | $21,256.58 | 2024-2025 | Jardiance |
| Vifor Pharma, INC. | $20,924.42 | 2019-2022 | |
| Amgen INC. | $9,942.11 | 2022-2025 | Krystexxa, Tavneos |
| Akebia Therapeutics INC | $9,227.16 | 2019 | |
| Janssen Pharmaceuticals, INC | $5,703.40 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,858.22 | 2019-2020 | |
| Calliditas Therapeutics US INC. | $295.92 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $250.00 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $240.00 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $154.80 | 2019 | |
| Advanced Oxygen Therapy INC. | $144.55 | 2025 | Topical Oxygen Chamber For Extremities |
| Mallinckrodt Enterprises LLC | $121.91 | 2019 | |
| Misonix INC | $118.47 | 2021 | |
| Abbott Laboratories | $65.63 | 2019 | |
| Solventum Corporation | $28.02 | 2024 | Activ.A.C., Promogran Prisma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.